COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Study to Evaluate Safety, of NextraTM in Surgery to Fuse the Proximal-interphalangeal- Joints

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01604070
Recruitment Status : Completed
First Posted : May 23, 2012
Last Update Posted : July 3, 2014
Information provided by (Responsible Party):
eMedtrain Inc.

Brief Summary:

Hammertoe deformity is the most common deformity of the lesser toes. It primarily comprises flexion deformity of the proximal interphalangeal (PIP) joint of the toe, with hyperextension of the metatarsophalangeal (MTP).

Etiologies of hammertoe deformity include a foot in which the second ray is longer than the first, MTP synovitis and instability, inflammatory arthropathies, neuromuscular conditions, and ill-fitting shoe wear. When a foot's second ray is longer than the first and shoe wear does not fit correctly, flexion of the PIP joint occurs to accommodate the shoe. This length difference also causes MTP synovitis to develop from overuse of the second MTP joint. Attenuation of the collateral ligaments and plantar plate result, and the MTP joint hyperextends and may even progress to dorsal subluxation or dislocation (see image below). Rheumatoid arthritis causes hammertoe deformity by progressive MTP joint destruction, leading to MTP joint subluxation and dislocation.

With all 3 of these etiologies, the extensor digitorum longus (EDL) tendon gradually loses mechanical advantage at the PIP joint, as does the flexor digitorum longus (FDL) tendon at the MTP joint. The intrinsic muscles fire and sublux dorsally, as the MTP hyperextends. They now extend the MTP joint and flex the PIP joint, as opposed to their usual functions of flexing the MTP joint and extending the PIP joint.

Condition or disease
Foot Diseases

Detailed Description:

Device Description:

Nextra implant is an anatomical 2-piece designed implant with 10° angulation with a locking fusion mechanism. The self-centering, metaphysis screw design allows a stable and secure relationship of the proximal and middle phalanges. The compression with progressive tightening approximates the bone surfaces for a controlled fusion.

Pre-clinical Data:

The Nextra Implant has been used to create fusions between the proximal and middle phalanges of the 2nd, 3rd. or 4th. toe.

Clinical Experience:

The NextraTM Implant has been used in humans as an implant to reduce hammertoe and contracture deformities.

2. STUDY OBJECTIVES: The primary objective is to evaluate the post-market safety and performance of NextraTM in the reduction of post-operative pain symptoms in hammertoes and demonstrate the efficacy of the implant to securely stabilize bone surfaces to be fused as to be compared to K-wire fixation.

3. STUDY DESIGN: General Design: Preoperative and post-operative factors will be assessed in the evaluation of efficacy and safety.

Layout table for study information
Study Type : Observational
Actual Enrollment : 98 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Randomized Multi-Center Post Market Clinical Study to Evaluate the Safety and Performance of NextraTM for Use in Foot Surgery to Fuse the Proximal-interphalangeal- Joints
Study Start Date : May 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Nextra fusion
group that has the nextra device
k wire fixation
control group fixated with k wire

Primary Outcome Measures :
  1. fusion [ Time Frame: 6 months ]
    proximal phalanx fusion

Secondary Outcome Measures :
  1. patient perception of outcome [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
This is a post market study and will consist of patients meeting the inclusion and exclusion criteria. The investigator recruits subjects if they meet the Inclusion/Exclusion requirements and are willing to sign an Informed Consent. Since the product is commercially available, randomization will occur at the time of surgery. Randomization will be according to a randomization table provided to the site investigators. The Surgeon will be unblended, and the subject will be blinded as to his/ her group (Treated-implant or Control-pin fixation).

Inclusion Criteria:

  • Pain in the toe reported for greater than 3 months.
  • Subjects are males or females,
  • Diagnosed with a hammertoe, contracture of the IPJ, or other condition,
  • Requiring digital proximal inter-phalangeal joint fusion of the 2nd, 3rd or 4th toe.
  • Unilateral deformity of a single digit (2nd, 3rd or 4th)
  • Subjects will sign an informed consent.
  • Subjects are willing to return for follow-up visits and fill out Quality of Life questionnaires

Exclusion Criteria:

  • Previous digital fusion surgery Previous PIPJ arthroplasty
  • Bilateral surgery Hallux valgus creating a crossover toe with 2nd toe
  • Inability to walk without an assistive device
  • Infection Rheumatic joint disease
  • Peripheral vascular disease with sensory loss to the toe
  • Pregnant
  • Osteoporosis
  • Obvious loss of digital bone density Severe respiratory disease
  • Open wounds
  • Patients presently taking Gabapentin (Neurontin), Pregabalin (Lyrica), etc. drugs for neuropathic pain
  • Diabetics
  • Narcotic dependence
  • Inability to consent to the research
  • Concurrent involvement in another clinical trial
  • Known allergy to the device components
  • Known metabolic bone disease
  • Renal disease (CRI, CRF)
  • Skeletal muscle spasticity or paralysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01604070

Layout table for location information
United States, Massachusetts
Cambridge Hospital
Cambridge, Massachusetts, United States, 02139
United States, New Jersey
Cumberland Orthopedic
Vineland, New Jersey, United States, 08360
United States, Virginia
Inova Alexandria Hospital
Alexandria, Virginia, United States, 22304
Mary Immaculate Hospital
Newport News, Virginia, United States, 23602
Sponsors and Collaborators
eMedtrain Inc.
Layout table for investigator information
Principal Investigator: Rick Jay, DPM Pennsylvania Hospital
Principal Investigator: Adam Landsman, DPM Cambridge Hospital
Principal Investigator: Michael Trepal, DPM Foot Clinics of New York
Principal Investigator: Nelson G Keller, DPM Mary Immaculate Hospital
Principal Investigator: Phillip Garrett, DPM Inova Alexandria Hospital
Layout table for additonal information
Responsible Party: eMedtrain Inc. Identifier: NCT01604070    
Other Study ID Numbers: Nextremity_2011
First Posted: May 23, 2012    Key Record Dates
Last Update Posted: July 3, 2014
Last Verified: July 2014
Keywords provided by eMedtrain Inc.:
Hammertoe deformity
Additional relevant MeSH terms:
Layout table for MeSH terms
Foot Diseases
Musculoskeletal Diseases
Skin Diseases